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Sepsis is characterized by Adult Respiratory Distress 
Syndrome (ARDS)-like pulmonary dysfunction largely 
attributed to alveolar capillary endothelial cell injury 
which causes increased microvascular permeability and 
interstitial edema formation. In addition, quantitative 
and qualitative abnormalities of the pulmonary surfac- 
tant system may be important features of some clinical 
and experimental lung injuries. This study was designed 
to investigate the relationship of bacteremia and endo- 
toxemia to pulmonary surfactant production in viva. A 
technique for estimation of pulmonary surfactant phos- 
pholipid synthesis measuring incorporation of a stable 
isotope precursor ([2- lSC]acetate) into dipalmitoylphos- 
phatidylcholine (DPPC) in alveolar lavage fluid waide- 
veloped. Male 350 g Sprague-Dawley rats had placement 
of central venous catheters. After overnight recovery, 
sublethal bacteremia (Escherichia coli, 1 X lOa organ- 
isms, iv) and sublethal endotoxemia (Difco; 10 mg/kg, iv) 
were induced. Both were associated with lung micro- 
vascular permeability increases consistent with capillary 
endothelial injury. Eight-hour infusions of [2-lSC]acetate 
were given. After sacrifice, bronchoalveolar washings 
and lung tissue were obtained and [2-13C] incorporation 
into lavage and lung DPPC was measured by gas chro- 
matography mass spectroscopy. Endotoxin-treated ani- 
mals had a 21.5% reduction in label incorporation into 
DPPC [1.215 ? 0.145 APE (%) sham versus 0.954 
? 0.144 APE (%) experimental, P > 0.051 and bacteremic 
animals had a 56.9% diminution of [2-“Clacetate incor- 
poration [1.215 + 0.145 APE (Yo) sham versus 0.524 
+ 0.56 APE (%) experimental, P < 0.051. Bacteremia- 
induced dysfunction of alveolar type II epithelial cells 
manifested as diminished alveolar surfactant phospho- 
lipid production may be a contributing factor to sepsis- 
induced respiratory failure. o 1989 Academic PEWS, h. 
1 Presented at the Annual Meeting of the Association for Academic 
Surgery, Salt Lake City, UT, November 16-19, 1988. 
‘Supported in part by The National Institutes of Health, Grant 
HL38141. 
INTRODUCTION 
Acute respiratory failure associated with sepsis is one 
of the primary causes of morbidity and mortality in a 
surgical critical care environment. Features of sepsis-in- 
duced acute lung injury include alveolar capillary endo- 
thelial injury, increased microvascular permeability, in- 
terstitial edema formation [l-4], intraalveolar hemor- 
rhage and fibrin deposition, influx of inflammatory cells 
(particularly neutrophils) [4, 51, complement activation 
[6,7], and alterations in the pulmonary arterial and cap- 
illary beds [8,9]. Both endotoxemia and bacteremia gen- 
erate acute lung injury experimentally and both are as- 
sociated with acute respiratory failure and ARDS clini- 
cally. 
The role of surfactant in ARDS-like acute lung injury 
is not entirely clear but has come under increasing scru- 
tiny in clinical and experimental lung injury [ 10-131. In 
particular, it was recently noted that ARDS-like oxygen 
radical-mediated lung injury is accompanied by altera- 
tions in alveolar surfactant properties [ 141. It has been 
known for some time that alveolar type II cells undergo 
proliferation and presumably increased surfactant pro- 
duction during the process of repair after lung injury [4, 
151. A variety of quantitative and qualitative surfactant 
deficiencies have been reported with acquired acute re- 
spiratory failure [ 10-131. These observations collectively 
suggest that loss of functional surfactant may contribute 
to ARDS-like acute lung injury. These deficiencies may 
result from diminished synthesis, diminished release, in- 
creased catabolism, or alterations in composition. The 
purpose of this investigation was to evaluate the processes 
of surfactant synthesis and alveolar distribution in re- 
sponse to experimental endotoxemia and bacteremia. Im- 
portantly, the methodology employed is applicable to hu- 
mans in that a stable isotope precursor ([2-13C]acetate) 
rather than a radioisotope was given and rates of incor- 
poration into small samples of alveolar lavage dipalmi- 
toylphosphatidylcholine (DPPC) were measured. 
Animal Model 
METHODS 
Male 350 g Sprague-Dawley rats were prepared by 
placing sterile Silastic central venous catheters (0.020 mm 
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internal diameter); (Dow Corning, Midland, MI) via the 
jugular vein and tunneling subcutaneously, exiting in the 
dorsal cervical region. Ketamine anesthesia (100 mg/kg, 
ip) was used and all protocols were approved by the Uni- 
versity of Michigan Review Committee for the Use of 
Laboratory Animals. After overnight recovery, the rats 
were placed in individual metabolic cages and randomly 
assigned to the following groups: (Controls) a l-ml iv bolus 
of physiologic saline was given (n = 9); (Escherichiu cd) 
a sublethal l-ml intravenous bolus of live bacteria (1 X 10s 
organisms/ml) was given (n = 6); or (Endotoxin) a 1 ml 
iv bolus of endotoxin, also a sublethal dose, was given 
(Difco,; LPS B, 026:B6; 10 mg/kg) (n = 5). 
E. Coli Preparation 
One milliliter of saline containing 10’ live E. coli (Dun- 
wald strain B15:0125) was given as an intravenous bolus 
at Time 0. The number of organisms was routinely de- 
termined by optical density and colony counts, and their 
viability assured by growth from blood cultures taken from 
the study animals [16]. 
Animal Protocol 
Following placement into one of the three groups, all 
animals received identical intravenous infusions of [2- 
i3C]acetate. Heparin flushes were not used in order to 
avoid heparin-induced changes in plasma fatty acid levels. 
[2-13C]acetate (Tracer Technology, Newton, MA) was 
administered intravenously to the unrestrained awake rats 
using a Harvard-type continuous infusion pump. Infu- 
sions were of physiologic saline with a concentration of 
approximately 6 pmole of acetate per milliliter for a dose 
adjusted to 10 pmole/kg/min. Infusions did not exceed 2 
ml per hour and were 8 hr in duration. At the conclusion 
of acetate infusion, sacrifice was immediate using an in- 
travenous ketamine bolus (100 mg/kg). Median sternot- 
omy was performed with extension into the neck. The 
trachea was isolated, ligated proximally, and cannulated 
with an la-gauge polyethylene catheter. Alveolar wash 
with 11 ml of saline was performed. We found that this 
volume visibly filled and distended all lobes of both lungs. 
This alveolar wash was aspirated and subsequently an- 
alyzed for phospholipid incorporation of [13C]acetate. Af- 
ter the alveolar wash, the right lung was excised, dividing 
the pulmonary hilum centrally. The pulmonary artery was 
cannulated using an 18-gauge polyethylene catheter and 
2.5 X magnification. Residual blood was eliminated from 
the specimen by two intravascular washes with 15 cc of 
sterile saline. Approximately 1 g of wet washed lung pa- 
renchyma was used for analysis of [ 13C]phospholipid con- 
tent. 
Alveolar Wash Analysis 
Usually 8-9 ml of saline was recovered from the rat 
lungs. Of this, a l-ml aliquot was added to 4 ml of chlo- 
roform:methanol(2:1) in a Teflon-lined screw-capped test 
tube and shaken vigorously for 1 min. The lower layer 
was transferred to a new tube and dried under Nz. The 
dried sample was redissolved in chloroform:methanol (2: 
1) for administration to TLC plates. Chloroform:meth- 
anol:2.5 N NHBOH (65:25:4) was used as solvent for thin- 
layer chromatography. Sample as well as phospholipid 
standard was administered to the plate. The plate was 
developed in an iodine chamber, after which the phos- 
pholipid band was scraped into a test tube and 1 ml BF3 
methanol was added and the tubes sealed tightly. The 
sample was incubated at 80°C for 15 min, and then 1 ml 
hexane was added and shaken for 1 min. The upper layer 
was transferred to new clean tubes, dried under Nz, and 
then redissolved in hexane for gas chromatography mass 
spectrometry analysis. Palmitate enrichment was deter- 
mined as described below. 
Lung Tissue Analysis 
Tissue (about 1 g) was added to 19 ml chloroform: 
methanol (2:l) and homogenized using a Brinkmann 
(Fisher, Fairlawn, NJ) tissue homogenizer. The sample 
was centrifuged, and 3.8 ml 0.88% KC1 was added. The 
upper phase was discarded, and 0.2 ml of the lower phase 
dried. The sample was then reconstituted in 50 ~1 chlo- 
roform:methanol (2:l) and spotted on the TLC plate. 
Sphingomyelin, phosphatidylcholine, P-ethanolamine, P- 
inositol, and P-serine derivatives for GCMS analysis were 
made as described for lavage, except for sphingomyelin. 
Sphingomyelin was extracted from the silica gel, then 1 
ml of 2% H&SO4 in anhydrous methanol was added, the 
tube sealed and heated at 90°C for 16 hr. One milliliter 
hexane and 0.1 ml HZ0 were added and the tube was 
shaken vigorously. The hexane layer (upper phase) was 
dried down, then taken back up in hexane for analysis. 
Palmitate enrichment was determined on the methyl ester 
of palmitate using a Hewlett-Packard 5985B gas chro- 
matograph mass spectrometer using electron impact ion- 
ization and selective ion monitoring of molecular ions at 
m/e 271 and m/e 272, as described in detail previously 
[ 171. Each sample was run in duplicate to ensure accuracy; 
the average enrichment for each sample was used for sta- 
tistical analysis. 
Lung Microvascular Permeability Assessment 
In separate animals identically prepared, an intrave- 
nous bolus [l ml of 1251-bovine serum albumin (BSA) 
(800,000 cpm)] was given 3 hr prior to sacrifice to assess 
microvascular permeability changes. Immediately follow- 
ing infusion, the rats were sedated with ketamine hydro- 
chloride (50 mg/kg, ip). Laparotomy was performed, 1 ml 
of blood was aspirated from the inferior vena cava (IVC). 
The IVC was transected to exsanguinate the animal. The 
heart and lungs were removed en bloc and 10 ml of sterile 
saline was infused into the right ventricle to wash residual 
blood and lz51-BSA from the pulmonary vascular bed. 
Done rapidly, a spontaneous heart beat persisted and the 
lung parenchyma developed a typical white blanched ap- 
pearance when bloodless. The whole lungs were counted 
OLDHAM ET AL.: BACTEREMIA AND PULMONARY SURFACTANT 399 
in a gamma scintillation counter with the 1 ml blood sam- TABLE 1 
ple. The ratio of lung to blood counts was taken as a 
measure of microvascular permeability and has been 
shown to be a reliable, quantifiable marker of lung injury 
Microvascular Permeability Index Changes Related 
to Time of Bacteremia and Endotoxemia” 
in this as well as other lung injury models [5, 71. This Time 
aspect of permeability assessment is described in detail after injection Sham Endotoxemia Bacteremia 
in several recent publications [5, 7, 181. 
- 
1 hr 0.146 + 0.03 0.258 -t 0.09 0.240 3~ 0.06 
Histology 
For histological study, additional rats were prepared 
identically without iz51-BSA injections. At sacrifice the 
lungs were inflated via the trachea with 4% glutaraldehyde 
in cacodylate buffer. After fixation, biopsies were taken 
from each lobe of the lung and embedded in epon. For 
light microscopy studies, l-pm sections were taken from 
the plastic blocks and stained with toluidine blue. For 
electron microscopy, ultrathin sections were cut and pro- 
cessed for ultrastructural analysis using a Philips 401 
transmission electron microscope (Philips Co., Amster- 
dam, The Netherlands). 
RESULTS 
Microvascular permeability data are presented in Table 
1. The data are expressed as the ratio of lung counts com- 
pared to a reference of counts per 1 ml of blood. This 
technique eliminates the variability inherent in injecting 
small volumes of a tracer and provides data which are 
intuitively interpretable. For example, a ratio of 0.20 in- 
dicates that 20% of the intravascular lz51-BSA label has 
been sequestered in the extravascular compartment dur- 
ing the experimental period. 
Evidence for Increased Microvascular Permeability and 
Endothelial Cell Injury (Table 1) 
One hour after induction of bacteremia or endotoxemia 
microvascular permeability is not statistically different. 
At later time points, 3 and 6 hr, the permeability index 
is significantly elevated, consistent with increased cap- 
illary permeability and the extravascular accumulation 
of the iz51-BSA. In addition, representative photomicro- 
graphs of normal and injured (endotoxin-treated) lung 
are shown at the 3-hr time point in Figs. la, lb, and lc. 
The histological features are not different for bacteremia 
and endotoxemia. These features include interstitial 
edema formation, alveolar capillary endothelial cell injury, 
neutrophil infiltration, and intraalveolar hemorrhage. 
Evidence for Diminished Precursor Incorporation into 
Bronchoalveolar Lavage and Lung Tissue 
Phosphatidylcholine (Table 2) 
All data are expressed as Atoms Percent Excess (APE) 
(%). This represents the fraction of 13C in the DPPC 
samples minus the naturally occurring background level 
of 13C and is expressed as a percentage. The data therefore 
3 hr 0.153 f 0.02 0.394 2 0.03* 0.397 k 0.05* 
6 hr 0.247 ?I 0.02 0.440 AZ 0.06* 0.475 * 0.15 
a Permeability Index calculated as lung/blood cpm (see text). 
* P < 0.05, Student’s t test compared to appropriate sham; (data ex- 
pressed as means _+ SEM). 
reflect the degree of sample enrichment attributable to 
infusion of the [2-13C]acetate precursor followed by syn- 
thesis into dipalmitolyphosphatidylcholine. The APE of 
lavage samples is taken then to reflect the rate of DPPC 
elaboration into alveolar surfactant. A detailed discussion 
of this calculation is recently provided [17, 191. The as- 
sumption is made here as it has been by others, that al- 
veolar lavage DPPC is derived principally from the con- 
tribution of alveolar surfactant [13, 201. 
Bronchoalveolar lavage DPPC 13C enrichment is sig- 
nificantly diminished (-56.9%) from baseline in rats with 
E. coli bacteremia (1.215 f 0.145% for controls versus 
0.524 * 0.056% for E. coli, P = 0.003). A similar assess- 
ment in rats with endotoxemia shows a diminished rate 
of precursor 13C incorporation (-21.5%) that does not 
achieve statistical significance (1.215 + .145% for controls 
versus 0.954 + .144 for endotoxin, P = 0.35). Hence, the 
rate of alveolar surfactant DPPC production appears sig- 
nificantly diminished with E. coli bacteremia. 
Lung tissue DPPC 13C enrichment is diminished in a 
parallel manner. Bacteremic animals have a significant 
reduction (-62.5%) from baseline of i3C incorporation 
into DPPC (1.116 t 0.217% for controls versus 0.418 
-t- 0.049% for E. coli-treated animals, P = 0.019). Rats 
with endotoxemia again show a reduction (-38.7%) that 
does not achieve statistical significance (1.116 ? 0.717% 
for controls versus 0.684 +- 0.221 for endotoxin, P = 0.293). 
DISCUSSION 
Based upon the hypothesis that biochemical change in 
surfactant phospholipid synthesis is likely to precede the 
gross physiologic alterations seen with clinical respiratory 
failure, we have developed a technique designed to eval- 
uate in vivo lung phospholipid synthesis. The utility of 
this technique includes human use, and possibly clinical 
use as a prognostic test for patients with early or im- 
pending respiratory distress. Unlike previous techniques 
using radioactive labels, this technique uses a stable iso- 
tope tracer ([2-i3C]acetate) and therefore presents no 
health risk. Additional advantages are that a very small 
phospholipid sample is sufficient so that alveolar wash 
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FIG. 1. Normal lung from sham rats is illustrated in panel a. Panels b and c from bacteremic and endotoxin-treated rat lung, respectively, 
illustrate the features of interstitial edema (c +), capillary endothelial cell injury with blebbing (4), and neutrophil sequestration (b). These 
are characteristic findings in the lungs of rats with either bacteremia or endotoxemia. (3150X) 
samples are practical. The use of stable isotopes makes 
this technique safe and specific. In addition, 13C enrich- 
ment of each fatty acid of each lipid can be individually 
quantitated so that investigation can reasonably be ex- 
tended beyond phosphatidylcholine. For example, the 
synthetic rate of phosphatidylglycerol, another lipid of 
interest in the pathogenesis of ARDS [4, lo], can also be 
estimated. 
In these particular experiments acute lung injury was 
induced separately by intravenous endotoxin injection and 
by live E. coli injection. Many of the systemic conse- 
quences of these insults are known. In particular acute 
lung injury with alveolar capillary endothelial injury and 
increased microvascular permeability has been charac- 
terized [l-4]. These proved to be important features of 
these sublethal sepsis models as well (Table 1 and Fig. 
1). Additionally this study examines the response of the 
lung to these injuries with regard to the phospholipid 
component of the surfactant system. 
Interest in the surfactant system in acute respiratory 
failure was initially derived from experience with pre- 
mature infants in whom a quantitative deficiency of sur- 
factant was clearly the primary etiology [13,21,22]. Adult 
respiratory failure and ARDS-like acute lung injury are 
multifactoral. Both quantitative and qualitative surfac- 
tant defects are recently described in ARDS-associated 
respiratory failure [lo-131. The nature of these defects 
appears to be specific for particular experimental models. 
The clinical implications of these observations are not 
yet clear. This study illustrates that the incorporation of 
a [2-r3C]acetate precursor into alveolar lavage dipalmi- 
toylphosphatidylcholine (DPPC) is diminished signifi- 
cantly in rats with E. coli bacteremia. 
TABLE 2 
The Effect of Endotoxemia and E. Coli Bacteremia on 
13C Enrichment of DPPC in Lung Tissue and 
Bronchoalveolar Lavage 
Intervention 
Lavage Lung tissue 
T! 13C 
enrichment % enrichment % 
APE (%) change APE (%) change 
Acetate alone 
(sham) 1.215 + 0.145 1.116 +_ 0.217 - 
Acetate 
+ E. coli 0.524 -c 0.056* -56.9% 0.418 k 0.49* -62.5% 
Acetate 
+ endotoxin 0.954 f 0.144 -21.5% 0.684 f 0.221 -38.7% 
’ 13C enrichment expressed as atoms percent excess (APE, %) (see 
text) 
* P < 0.05 compared to appropriate Sham, Student’s t-test 
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Surfactant itself is a complex moiety composed of pro- 
tein, carbohydrate, and phospholipid components. The 
phospholipid component is not independently sufficient, 
but contributes substantially to its physiologic role as a 
surface-active substance coating alveoli which reduces 
surface tension and maintains alveolar inflation. Of the 
surfactant phospholipids produced by alveolar type II 
cells, DPPC is the most abundant, representing approx- 
imately 50% of the total [20]. Indeed, therapeutic trials 
of artificial surfactants have focused upon strategies for 
replacing alveolar DPPC [ 131. For this reason DPPC was 
selected as the index alveolar phospholipid in these ex- 
periments. As noted, other phospholipids can be assessed 
with this methodology and may well yield important find- 
ings. 
A potential criticism of the approach proposed is that 
the bronchoalveolar lavage specimens obtained might not 
reflect the alveolar surfactant pool accurately. Although 
this could be true, a number of previous investigators have 
validated the general concept of bronchoalveolar lavage 
evaluation for surfactant sampling [lo, 201. King and 
Clements pooled data from different laboratories and 
found that the phospholipid composition of rat alveolar 
epithelial type II cells, rat type II cell lamellar bodies, and 
rat pulmonary surfactants purified from lavage fluid are 
similar [20]. In this series of experiments, we have ob- 
tained distributions of phospholipid species in rat bron- 
choalveolar lavage specimens similar to those reported by 
King and Clements [20]. Additional support for the as- 
sumption that lavage phospholipids reflect type II cell 
phospholipid composition is provided by the data for lung 
tissue DPPC rates of 13C enrichment. The parallel changes 
in the lung tissue DPPC and lavage enrichment rates are 
clear in Table 2. This suggests that cellular pools as well 
as extracellular phospholipid pools (including alveolar 
surfactant) are affected similarly by the injury. Although 
the lung tissue phospholipid pool does include cell pop- 
ulations other than the type II cells, the similar response 
to endotoxemia and bacteremia is consistent with the hy- 
pothesis that type II cell production of surfactant phos- 
pholipid is diminished by these injuries. Finally, it should 
be emphasized that one goal of the methodology developed 
was to provide a simple and potentially useful clinical 
analysis. Clearly a benign approach such as obtaining 
bronchoalveolar lavage is required for patient use. We 
have found that reproducible alterations in the 13C en- 
richment in lavage phospholipids occur with experimental 
lung injuries associated with surfactant abnormalities. 
These injuries include acute pancreatitis [ 191, exposure 
to hyperbaric oxygen (unpublished data), and here, bac- 
teremia and endotoxemia. These data suggest potential 
clinical utility using lavage phospholipid specimens. More 
recently, we have used this approach in a small number 
of human patients and 13C enrichment of lavage specimens 
is demonstrable. In summary, we have made the assump- 
tion, as have others, that a relationship exists between 
lavage and alveolar surfactant phospholipid composition. 
Given the inherent limits imposed by this assumption, 
the data provided do suggest that the method of sampling 
proposed is practical, and bronchoalveolar lavage DPPC 
enrichment does reflect a variety of acute lung injuries 
for which surfactant abnormalities are suspected. 
We conclude that rats with E. coli bacteremia have sig- 
nificantly reduced synthesis of the DPPC component of 
alveolar surfactant as reflected in bronchoalveolar lavage 
samples and assessed by [2-13C]acetate incorporation. 
Rats with endotoxemia have similarly lower rates of 13C 
incorporation but the changes in these experiments do 
not achieve statistical significance. These data suggest 
that sepsis-induced acute lung injury and respiratory fail- 
ure may be associated with a failure of alveolar type II 
cell phospholipid synthesis and a resultant deficiency of 
functional surfactant. The stable isotope analytical tech- 
nique described for lavage DPPC evaluation by GCMS is 
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